Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470847 · ClinicalTrials.gov registry record · Phase 1
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
A Phase 1 study, sponsored by Nancy Lin, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00470847: Completed Phase 1 study, sponsored by Nancy Lin, MD.
NCT00470847 is a Phase 1 study that has completed, run by Nancy Lin, MD. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470847, a Phase 1 study, has completed, sponsored by Nancy Lin, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cells from growing abnormally. It is thought that lapatinib might also make cancer cells more sensitive to radiation. This drug has been used in other research studies in women with breast cancer, and information from those other research studies suggests that lapatinib may help to shrink or stabilize breast tumors both inside the brain and outside the brain.
Primary Outcome
The maximum tolerated dose is defined as :The highest dose of a drug or treatment that does not cause unacceptable side effects.
Interventions
- DRUG Lapatinib
- DRUG Herceptin
- PROCEDURE Whole Brain Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT00470847 record still lists
NCT00470847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Lapatinib is the first listed.
NCT00470847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00470847 about?
NCT00470847 is a clinical study titled "Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer". The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cel...
What is the current status of trial NCT00470847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2007-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00470847?
The interventions under investigation include: Lapatinib (DRUG), Herceptin (DRUG), Whole Brain Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00470847?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00470847's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia